Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer’s Announcement
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Pfizer has just announced that a person with hemophilia, in their marstacimab (Hympavzi) clinical trial program, has died from a thrombotic stroke.
I attach the letter they sent to a number of patient organisations including the World Federation of Hemophilia.
The information provided in the letter is minimal.
I hope they reach out to all hemophilia doctors worldwide who can potentially prescribe this drug to inform them about this event, and the other thrombotic event in the same clinical trial that was previously disclosed at the EAHAD and ISTH meetings.
The patient who died, had hemophilia A with an inhibitor.
Marstacimab is at present only approved for persons with hemophilia A and B without an inhibitor.”
Stay updated with Hemostasis Today.
-
Jul 7, 2026, 20:59William Aird: An Unlucky Turn Into the Renal Artery
-
Jul 7, 2026, 20:58Chokri Ben Lamine: The Two-Hit Model of TRALI
-
Jul 7, 2026, 20:57New Issue of Blood Out Now – Blood Journals Portfolio
-
Jul 7, 2026, 20:56Priyadarshini Ramakrishnan: Schistocytes – The Most “Misleading Heroes” in a Peripheral Smear
-
Jul 7, 2026, 20:55Natasa Blagojevic-Stokic: Exploring the Role of ATP and Calcium Homeostasis in Autism
-
Jul 7, 2026, 17:49Alan Nurden: Safer Antithrombotic Therapy Through GPVI
-
Jul 7, 2026, 17:29Anticoagulation Reversal in 2026: Are We Winning the Bleeding Battle? – Francisco Chacón-Lozsán
-
Jul 7, 2026, 17:25Jim Hoffman: Targeting NETosis to Restore Immune Homeostasis
-
Jul 7, 2026, 17:14Shabneez Hussain: Blood Transfusion Professionals Connecting at ISBT 2026